Jasper Therapeutics logo

Jasper Therapeutics

JSPR | NASDAQ
Chart Builder DCF Calculator
$11.77
-$1.91 (-13.96%)
At close: Nov 16, 2026, 4:00 PM ET
$12.41
+$0.64 (+5.44%)
After-hours: Nov 16, 2026, 7:30 PM ET
-13.96%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
29.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #806/1021 (Top 79%)

Key Statistics

Market Data

Market Cap $13.05M
1D Range
11.77 14.35
52W Range
10.23 61.50

Valuation (TTM)

PE -0.25
PB 9.24
EV/EBITDA -0.19

Valuation (NTM)

Forward PE N/A
Forward PEG 0.00
Price Target $2.50
Loading financial charts...

Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate i...

Sector Healthcare
Industry Biotechnology
Employees 22
IPO Date Jan 10, 2020
Fiscal Year January - December

Latest News

Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants

8 days ago · globenewswire.com

Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split

13 days ago · globenewswire.com

Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

1 month ago · globenewswire.com

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

1 month ago · globenewswire.com

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

2 months ago · globenewswire.com

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

2 months ago · globenewswire.com

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

3 months ago · globenewswire.com

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Earnings

Latest Earnings
Nov 16, 2026
EPS
-$10.19
Miss -475.71%
REV
$8M
Beat +33.33%
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Hold
Price Target
$2.00
Downside
-83.01%
Buy (1)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.